KVUE - Kenvue Inc Debt to Book Capitalization Ratio

Graphic logo of Kenvue Inc (KVUE)

Kenvue Inc. (KVUE) focuses on cost optimization and margin growth for its top brands. The company's debt-to-book capitalization ratio visualizes this trend, while the 0.84 indicator confirms the current level of financial stability. Effective management following the spin-off from J&J guarantees dividends, although pressure from retailers' private labels and high marketing expenditures create significant market risks.

KVUE (Kenvue Health) Debt to Book Value history from 02/21/2024 to 10/28/2026
Core merchandise of Kenvue Corp

This ratio measures the proportion of borrowed funds within the overall capital structure, determining Kenvue Inc. (KVUE) dependence on creditors and its resilience to market shocks. Job stability and a strong brand confirm a margin of safety; therefore, analyzing the debt-to-capitalization coverage ratio allows an investor to assess the balance between financial leverage and the company's efficient resource utilization.

Competitors of Kenvue Inc.

Debts to Book Capitalization HLN (Haleon plc)|veronapharma.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Jyong Biotech (MENS)|LGND: Debt to Net Assets Ratio|AMRX (Amneal Pharmaceuticals Inc) - Debt to Book Capitalization Ratio|Perrigo Corp (PRGO) - Debt to Book Value|ALVO (Alvotech) - Debts to Book Capitalization|Debts to Book Capitalization liquidia.com (LQDA)|Galapagos (GLPG) - Debt to Book Value|Debt to Net Assets Ratio ANIP (ANI Pharmaceuticals Inc)|MNKD: Debt to Book Capitalization Ratio|AMPH - Debts to Book Value|Debt to Book Value Pacira BioSciences PCRX|SPRY - Debt to Book Capital|Debts to Book Capitalization Theravance Biopharma, Inc. TBPH|Aquestive Therapeutics Inc (AQST) - Debt to Net Assets Ratio|Debts to Book Capitalization SCPH (scPharmaceuticals, Inc.)|Debts to Book Value TECX|Tonix Pharmaceuticals (TNXP) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio SXTC (sxtchina.com)|Debt to Book Capitalization Ratio EPRX (Eupraxia Pharmaceuticals Inc.)|Debts to Book Capitalization BioHarvest Sciences, Inc. BHST|EXOZ (Invizyne Technologies, Inc.) - Debts to Book Capitalization|ORMP: Debts to Book Value|Debt to Book Capitalization Ratio enterabio.com|Debt to Book Value Ratio ipatherapeutics.com|Debt to Book Value ABVC BioPharma, Inc.|Debt to Book Capitalization Ratio Cumberland Pharmaceuticals Inc (CPIX)|Debt to Book Value QNTM|Debts to Book Capitalization FibroGen Corporation (FGEN)|TELO: Debts to Book Capitalization|RANI - Debts to Book Value|Debt to Book Value Synergy CHC Corporation (SNYR)|RLYB - Debt to Net Assets Ratio|lexariabioscience.com - Debts to Book Capitalization|PULM (Pulmatrix Corporation) - Debts to Net Assets|Debt to Book Capitalization Ratio Pheton Holdings Limited (PTHL)|Debt to Book Value Ratio Aptorum|Debts to Book Capitalization LYRA (Lyra Therapeutics)|Debt to Book Value Impact BioMedical, Inc. IBO|Debt to Book Value TNFA|cbdMD Inc. - Debts to Net Assets|PainReform Ltd. - Debt to Book Capitalization Ratio|Altamira Therapeutics (CYTO) - Debts to Book Capitalization|Lipella Pharmaceuticals, Inc. (LIPO) - Debt to Book Value|Debt to Book Capitalization Ratio OptiNose Inc|PIRS (Pieris) - Debt to Book Value|Debts to Book Capitalization Procaps Group Corp|Petros Pharmaceuticals - Debts to Book Capitalization|Debts to Book Value QLI (qlsyy.net)|ACELYRIN (SLRN) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio TFF Pharmaceuticals Inc. TFFP